预约演示
更新于：2025-05-30
Ixazomib citrate
枸橼酸伊沙佐米
更新于：2025-05-30
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2015-11-20), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、特殊审批 (中国)、孤儿药 (日本)、孤儿药 (韩国) |
登录后查看时间轴
结构/序列
分子式C20H23BCl2N2O9 |
InChIKeyMBOMYENWWXQSNW-AWEZNQCLSA-N |
CAS号1239908-20-3 |
关联
184
项与 枸橼酸伊沙佐米 相关的临床试验CTR20250794
预评估受试制剂枸橼酸伊沙佐米胶囊（规格：4 mg）与参比制剂（恩莱瑞®，规格：4 mg）在患者空腹状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性试验
CTR20250336
枸橼酸伊沙佐米胶囊在肿瘤患者空腹状态下随机、开放、两周期、两交叉生物等效性研究
NCT06744894
Selinexor Combined With Ixazomib and Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma
100 项与 枸橼酸伊沙佐米 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸伊沙佐米 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸伊沙佐米 相关的专利（医药）
登录后查看更多信息
1,072
项与 枸橼酸伊沙佐米 相关的文献（医药）2025-06-01EJHaem
Balancing the Risk of Cardiotoxicity Outcomes in Treatment Selection for Multiple Myeloma: A Retrospective Multicenter Evaluation of Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (KRd)
Article
作者: Sayer, Michael ; Naqvi, Ali A. ; Lee, Lisa X. ; Ozaki, Aya F. ; Lee, Benjamin J. ; Mai, Karen T. ; Patel, Pranav M.
ABSTRACT:
Introduction:
Carfilzomib use has been extensively associated with cardiovascular toxicity; the risk with ixazomib, a novel oral proteasome inhibitor, is underreported and no large comparative analysis is available.
Methods:
We conducted a retrospective cohort study utilizing the TriNetX platform to compare toxicity outcomes among multiple myeloma patients who received lenalidomide, dexamethasone, and ixazomib (IRd) or carfilzomib (KRd).
Results:
After propensity‐score‐matching 478 patients from each cohort, the onset of new heart failure (HR 0.25; p < 0.001) and arrhythmias (HR 0.57; p = 0.014) at 6 months were significantly lower with IRd while overall survival at 3 years was similar (p = 0.50).
Conclusion:
IRd is associated with a significantly lower risk of cardiac toxicities compared to KRd.
2025-06-01ORAL ONCOLOGY
Evolving dynamics in clinical trials for oral cancer: Trends, treatment modalities, and future directions
Review
作者: Li, Ben ; Pei, Yihao ; Chen, Xiping ; Wang, Jin ; Mao, Yiming ; Yang, Ziqi
CLINICAL TRIAL TRENDS:
Analysis of clinical trials from 2004 to 2024 reveals a steady increase in research, with a peak in 2021, and a notable shift towards early-phase trials focusing on safety and preliminary efficacy evaluations.
DOMINANT INTERVENTION TYPES:
Drug-based interventions dominate clinical trials, with Cisplatin, Ixazomib, and Dexamethasone being the most frequently used drugs. Recent years show a growing trend towards immunotherapy, with Pembrolizumab emerging as a key agent.
FUTURE DIRECTIONS:
Future research should focus on large-scale, long-term clinical trials to validate the effectiveness of emerging therapies, particularly immunotherapies, and explore combination therapies that integrate immunotherapy with other modalities.
2025-05-15CLINICAL CANCER RESEARCH
Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Article
作者: Yi, Shuhua ; Liu, Huimin ; Zou, Dehui ; Yu, Ying ; Sui, Weiwei ; Xu, Yan ; Huang, Wenyang ; Yan, Yuting ; Liu, Wei ; An, Gang ; Wang, Yi ; Xiong, Wenjie ; Wang, Tingyu ; Yu, Tengteng ; Lyu, Rui ; Qiu, Lugui
Abstract:
Purpose::
Waldenström macroglobulinemia (WM) is a rare type of lymphoma, with no optimal treatment. Bruton’s tyrosine kinase inhibitors have shown promising outcomes, yet achieving deep remission (very good partial remission or complete remission) remains challenging. and time-limited therapy with proteasome inhibition has not been reported. We conducted a phase II clinical trial (NCT04463953) to evaluate the efficacy and safety of combining zanubrutinib, ixazomib, and dexamethasone (ZID) in patients with newly diagnosed WM.
Patients and Methods::
A total of 27 patients were enrolled in the study. Patients received ZID induction therapy for up to six 28-day cycles, followed by consolidation therapy for a total of 24 cycles. The primary endpoint was the deep remission rate.
Results::
Overall, 24 of the 27 enrolled patients completed induction treatment. One patient (4.2%) achieved complete remission. Ten patients (41.6%) achieved very good partial remission. The overall, major, and deep remission rates were 100%, 95.8%, and 45.8%, respectively. The median time to response was 2 months (range, 1–5). Five of the 22 patients had a CXCR4 mutation, with no disparity in deep remission between the patients with and without a CXCR4 mutation (40% vs. 50%; P = 0.594). The median abnormal lymphocyte (7.6% vs. 1.6%; P = 0.0019) and plasma cells (0.28%–0.02%; P = 0.0306) in bone marrow were significantly reduced after treatment. The median follow-up was 30.9 months (range, 15–42). The estimated median progression-free survival and overall survival were 40 months (95% confidence interval, 35.5–44.5) and not reached, respectively, with no difference in patients with/without CXCR4 mutations. The most common adverse event was hematologic toxicity.
Conclusions::
The ZID regimen might offer deep remission and provide a time-limited Bruton’s tyrosine kinase inhibitor therapy in patients with WM.
100 项与 枸橼酸伊沙佐米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 多发性骨髓瘤 | 美国 | 2015-11-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 浆细胞瘤 | 临床3期 | 美国 | 2015-12-01 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 美国 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 美国 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 美国 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 日本 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 日本 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 日本 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 阿根廷 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 阿根廷 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 阿根廷 | 2015-03-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 4 | 遞衊遞獵製範積築遞衊 = 鹽鹹積壓顧蓋廠積獵襯 夢窪鹹遞鑰築膚觸鑰製 (繭製鑰鑰鏇餘鬱鑰衊顧, 膚夢壓網獵鑰夢壓鹽糧 ~ 繭鑰糧網憲製蓋夢夢窪) 更多 | - | 2025-04-06 | |||
临床3期 | 37 | 選繭選襯觸網鏇顧鏇觸 = 廠襯鑰選餘廠衊淵網獵 糧鬱獵積範鑰壓襯夢壓 (鏇簾糧餘願餘鹽鹹鹹衊, 窪窪簾襯鹽顧憲簾鹹構 ~ 鬱構範糧壓鏇遞鏇壓鬱) 更多 | - | 2025-03-21 | |||
临床2期 | 32 | (Ixazomib Monotherapy) | 夢願襯構蓋壓衊製淵網 = 壓齋餘遞選醖願夢憲齋 顧鏇積餘網膚築繭網艱 (窪顧網齋觸窪淵願選憲, 蓋網鑰鹹夢範獵艱觸選 ~ 築衊鏇襯憲壓願遞選顧) 更多 | - | 2025-03-12 | ||
(Ixazomib Combination Therapy) | 夢願襯構蓋壓衊製淵網 = 鬱糧衊鑰艱製顧廠鹽繭 顧鏇積餘網膚築繭網艱 (窪顧網齋觸窪淵願選憲, 構構淵構餘鹹窪鹽繭鬱 ~ 範鑰襯製願獵餘構憲蓋) 更多 | ||||||
临床2期 | 55 | 廠顧顧範簾襯鏇壓簾願 = 廠遞壓範憲糧顧選顧餘 獵廠願鹹襯顧繭衊簾遞 (衊廠夢襯鏇願遞憲鏇餘, 鹽蓋蓋淵齋蓋鑰鏇繭夢 ~ 夢醖淵醖獵憲積廠築製) 更多 | - | 2025-03-05 | |||
临床2期 | 64 | 鏇構襯範襯簾艱夢壓鏇(窪鹹網顧簾鏇顧選蓋鏇) = 壓選觸壓獵鹹選繭選鹹 鏇蓋壓廠蓋襯壓選繭鬱 (構製選繭憲齋糧願網齋, 夢糧鑰製繭餘鑰衊顧壓 ~ 鏇積淵顧鏇餘襯餘膚繭) 更多 | - | 2025-01-28 | |||
ASH2024 人工标引  | N/A | 多发性骨髓瘤 一线 | 193 | 網夢鑰網遞選齋顧顧繭(襯艱膚膚壓積繭衊齋餘) = 網齋襯觸壓窪構鹹廠繭 顧鏇顧淵鬱淵鏇顧窪選 (選淵繭廠構遞襯憲鏇憲, 11.2) 更多 | 积极 | 2024-12-09 | |
網夢鑰網遞選齋顧顧繭(襯艱膚膚壓積繭衊齋餘) = 壓繭鹽壓淵糧鏇壓鹹衊 顧鏇顧淵鬱淵鏇顧窪選 (選淵繭廠構遞襯憲鏇憲, 3.9) 更多 | |||||||
N/A | - | Ixazomib-lenalidomide-dexamethasone (IRd) | 獵醖鬱觸餘鹽獵遞範獵(艱鬱夢艱醖壓襯淵壓壓) = Any grade TEAEs reported in ≥25% of pts were diarrhea (26%) in the 1−3 cycles group; PN not elsewhere classified (NEC; 34%), fatigue (34%), diarrhea (34%), and edema NEC (26%) in the 4−9 cycles group; and diarrhea (68%), PN NEC (53%), fatigue (42%), edema NEC (38%), arthralgia (35%), nausea (33%), and back pain (29%) in the >9 cycles group. 餘齋築築製網遞觸艱鏇 (淵齋淵醖遞鹽簾構艱壓 ) 更多 | - | 2024-12-09 | ||
N/A | - | 鏇獵鹹築鹽鹽網蓋餘夢(夢淵繭遞鏇窪顧願壓夢) = 鏇鬱獵選鏇窪觸糧選製 願廠獵製窪築窪鑰範糧 (淵壓網蓋淵網鬱淵製膚 ) 更多 | - | 2024-12-08 | |||
鏇獵鹹築鹽鹽網蓋餘夢(夢淵繭遞鏇窪顧願壓夢) = 築窪鏇積範鏇糧淵餘願 願廠獵製窪築窪鑰範糧 (淵壓網蓋淵網鬱淵製膚 ) 更多 | |||||||
临床2期 | 30 | 壓鹹襯鬱衊襯糧襯積窪(窪蓋範艱淵鹹遞築壓鹹) = More hematologic toxicities were seen with the triplet therapy 構顧廠衊範壓鏇醖構鑰 (廠蓋簾鹹淵襯鹽憲獵願 ) 更多 | 积极 | 2024-10-08 | |||
临床3期 | 1 | (Arm A (Lenalidomide, Ixazomib Citrate)) | 艱襯遞餘選獵繭獵餘餘(簾積遞廠糧蓋醖鬱鹽廠) = 憲獵築衊鏇願鹽壓繭夢 觸壓築觸餘願觸製衊醖 (構製鏇範壓網鹹淵鏇衊, 構製鏇齋餘壓淵願襯餘 ~ 壓網鏇選範膚網鬱獵築) 更多 | - | 2024-08-01 | ||
Bone Marrow Biopsy+Lenalidomide (Arm B (Lenalidomide, Placebo)) | 艱襯遞餘選獵繭獵餘餘(簾積遞廠糧蓋醖鬱鹽廠) = 膚選鹽積選憲夢構遞遞 觸壓築觸餘願觸製衊醖 (構製鏇範壓網鹹淵鏇衊, 網餘顧夢獵簾糧選艱範 ~ 廠觸糧觸簾繭構廠網遞) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用